Not all cancer patients need chemo – Ataraxis AI raised $ 20 million to customize treatment

Artificial intelligence is a great trend in cancer care and is most focused on the detection of cancer at the most possible stage. This makes a lot of sense, given that the cancer is less deadly, the earlier it is discovered.

But less ask another basic question: if anyone has cancer, aggressive treatment such as chemotherapy is needed? This is the problem that ATARAXIS AI is trying to solve.

Starting, based in New York, focuses on using AI to precisely predict not only whether the patient has cancer, but also what their cancer result looks like for five to 10 years. If there is only a little chance that the cancer will return, the chemo can be avoided completely – saving a lot of money, while avoiding the famous side effects of treatment.

Ataraxis AI is now planning to launch its first commercial test, for breast cancer, for us oncologists in the coming months, its co -founder Jan Vitovski told TechCrunch. In order to strengthen the start and expand in other cancers, the starter has collected a $ 20.4 million Serie A, he told TechCrunch exclusively.

The circle was led by Aix Ventures starring Thiel Bio, Fund’s founders, Flating Point, Bertelsmann and existing giant investor endeavors and obvious endeavors. Atrakssis appeared From Stealth last year with a round of $ 4 million seeds.

Ataraxis is the co -founder of Witowski and Krzysztof Geras, an associate professor at the NYU Medical School, who focuses on AI.

Ataraxis technology is powered by an AI model that extracts information from images of high resolution cancer cells. The model is trained in hundreds of millions of real images from thousands of patients, Vitovski said. A recent study showed that Ataraxis technology was 30% more accurate than the current standard of breast care for breast cancer.

Long -term, Ataraxis has great ambitions. He wants his tests to influence at least half of new cases of cancer by 2030. It is also regarded as a border AI company that builds its own models, taking into account Meta Yann Lecun’s chief scientist As an AI adviser.

“I think at Ataraxis we try to build what is essentially AI Frontier Lab, but for health applications,” Vitovski said. “Because so many of these problems require a very new technology.”

The AI ​​boom has led to a tide of raising funds to start cancer. Valar Labs raised $ 22 million To help patients understand their treatment plan in May 2024, for example. There are also numerous drug detection companies powered by AI raised $ 24.6 million in January 2025. And he was the co -founder of Reed Hoffman, the co -founder of LinkedIn.